There is no vaccine available for T. vaginalis. The most effective prevention is abstinence; however, sexually active persons can limit risk of infection by practicing safer sex including using latex condoms or polyurethane dental dams to avoid contact with sexual fluids.

Because only 30 percent of people with T. vaginalis  have symptoms, many people spread the disease without knowledge of infection. Getting tested and receiving treatment is recommended to help prevent the problem of reinfection.

Diagnostic testing is recommended for all women presenting symptoms of vaginitis. The diagnosis of trichomoniasis traditionally was based on morphologic identification of the organism in a wet mount preparation of a swab from vaginal discharge fluid in women or urethral exudate in men. Microscopic evaluation of wet mounts has a positive predictive value negative predictive value of only 60 percent, which can be increased to over 80 percent with direct immunofluorescent antibody staining. Parasitic culture, though more sensitive, requires several days to complete and is infrequently done. A rapid diagnostic point-of-care dipstick test is available and has reasonably high sensitivity and very high specificity. Molecular diagnostic methods based on PCR offer high sensitivity and specificity.

Treatment with oral antibiotics is highly effective for curing trichomoniasis. Medications include:

• Metronidazole
• Tinidazole
• Secnidazole

Treatment of sexual partners is recommended to reduce reinfection rates.

• https://www.cdc.gov/std/trichomonas/stdfact-trichomoniasis.htm
• https://my.clevelandclinic.org/health/diseases/4696-trichomoniasis
• https://www.cdc.gov/std/trichomonas/default.htm